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THE activity of phospholipase A2 in human gingival
crevicular fluid (GCF) associated with periodontal disease
was demonstrated. Based upon the presence or absence of
bleeding on probing (BOP), which is a marker for the
disease activity, there were higher levels of the enzyme
activity in BOP positive, than in negative sites. When the
BOP positive sites became negative after periodontal
therapy, the enzyme activity decreased dramatically to
almost undetectable levels. There were no significant
differences between the activity before and after treatment
when the BOP positive sites remained unchanged. These
results suggest that the activity in GCF reflects periodontal
disease conditions and that it can be used as a marker for
disease activity.
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Introduction
Phospholipase A2 (PLA2) is a key enzyme in the
production of potent inflammatory mediators,
namely prostaglandins, leukotrienes and platelet
activating factor. In fact, high levels of PLA2
activity have been found in either the sites and/or
sera of patients with various inflammatory diseases
such as rheumatoid arthritis,2’3 acute pancreatitis,
4,s
inflammatory bowel disease,
6 and septic shock.7
Furthermore, PLA2 activity in human synovial
cells, rat astrocytes,
9 and rabbit articular chondro-
cytes
1 was markedly induced in response to
inflammatory cytokines such as interleukin 1 (IL-1)
and tumour necrosis factor (TNF). The serum PLA2
activity in some of those conditions correlates with
disease activity.6’11’12 Collectively, these results
suggest that PLA2 plays an important role in the
process of inflammatory disease and that the
determination of the activity can be a useful tool
for diagnosis.
Periodontitis, an infectious disease which leads
to destruction of the periodontal tissue, is a major
cause of tooth loss in adults. Gingival crevicular
fluid (GCF) is an exudate from periodontal tissue
that contains various inflammatory mediators. For
example, higher levels of PGE2 and IL-1 have
been detected in GCF13’14 as well as in periodontal
tissue15’16 from patients with periodontal disease
than in normal subjects. Recently, the authors
characterized PLA2 activity in healthy rat gingiva
17
and showed that it is regulated by inflammatory
cytokines in rat gingival fibroblasts. 18’19 These
results suggested that there should be PLA2 activity
in GCF in periodontal patients. However, there
(C) 1994 Rapid Communications of Oxford Ltd
have been no reports describing PLA2 activity in
human periodontal sources associated with either
healthy or inflamed conditions. Here, PLA2 activity
in GCF in patients is demonstrated and the
relationship between the enzyme and periodontal
disease activity is discussed.
Material and Methods
Patients" Thirty-two patients ranging in age from
25 to 73 years with a mean _S.E. of 43.5_ 1.9
years were enrolled in this study. All the patients
were diagnosed as having at least several teeth with
the disease and none had received any medication
or periodontal therapy prior to the study. The
periodontal conditions of each patient were
evaluated by the depth of periodontal pocket
(pocket probing), a marker of periodontal tissue
20 destruction and bleeding on probing (BOP), a
marker of the active phase of the disease.21
GCF sampling: GCF was sampled from 108 sites of
the 32 patients at the first visit, and in some
experiments, 19 sites were selected from which to
sample GCF before and after periodontal therapy.
GCF sampling was performed according to the
procedure of Kryshtalskyj et aL22 using a 2 #1 micro
capillary tube (Drummond Sc. Co., USA). Briefly,
after careful removal of supragingival dental plaque
the tube was gently placed near the bottom of the
periodontal pocket for 30 s. After sampling, the
tube containing the sampled GCF was swiftly
removed, the volume was measured, and the GCF
in the tube was eluted into 200 #1 of assay buffer
containing 50 mM Tris-HC1 (pH 7.4) with 10 mM
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CaC12. The samples were stored at -20C until the
assay for PLA2 activity.
Gingival tissues, blood samples and saliva: Inflammatory
gingival tissues were taken from the seven sites of
seven patients immediately after collection of GCF
upon pocket curettage (a periodontal therapy). The
tissues were rinsed thoroughly with ice-cold
isotonic solutions, weighed, then minced and
homogenized in 50 mM Tris-HC1 (pH 7.4) using
a glass homogenizer immersed in ice-cold water,
followed by centrifugation at 1 500 x g for 30 min.
The supernatant was used as the enzyme source (the
supernatant). Blood samples were collected after
GCF sampling, at six sites where BOP was observed
and saliva was collected from the mouths of six
patients with a micro capillary of the same size as
that described above.
Enwme assay: The assay for PLA2 activity was
performed using the modified methods of Nishijima
et al.
23 and Shakir.24 Briefly, the assay mixtures
contained 50 mM Tris-HC1 (pH 7.4), 10 mM CaCI2
and 10 #M of 1-acyl-2-[1-14C]-arachidonyl phospha-
tidylethanolamine (PE) (Amersham, UK) as the
substrate. The incubation was initiated by adding
the sample (GCF, the supernatant, blood, or saliva)
to the reaction mixture and incubating at 37C for
3 h. PLA2 activity was determined by measuring the
amount of [1-14C]-arachidonic acid released from
the radiolabelled PE as described previously.
7
Statistical ana(ysis" Data are expressed as means-+-
S.E. All data were analysed by means of the Pearson
product moment correlation coeflCicients, the
Mann-Whitney U test, or the Wilcoxon signed-rank
test, as appropriate. The analyses were carried out
on an Apple Macintosh Quadra 700 computer
(Apple Computers, Cupertino, CA, USA)using
Statview plus (Brain Power, Calabasas, CA, USA)
software, p < 0.05 was considered the minimal
significant value.
Results
GCF samples taken from 108 sites of 32 untreated
periodontal patients were assayed for PLA2 activity
(Fig. 1). About half (56 sites) of the sampled GCF
had measurable PLA2 activity while the other half
(52 sites) had undetectable activity under our assay
conditions. The levels of PLA2 activity showed
a wide range of total activity ranging from 2.4
to 291.0 pmol/h/sample with a mean ___S.E. of
32.4 + 6.0.
Figure 2(A) and (B) show the relationship
between PLA2 activity in GCF and the GCF volume
or probing depth. The volume and probing depth
varied from 0.05 to 1.40 #1 with a mean +/- S.E.
(n 108) of 0.30 _+ 0.02/zl and from 2 to 11 mm
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FIG. 1. Frequency histogram of PLA2 activity in GCF from the sites at the
first visit. The frequency distributions showed that about half of the sites
examined had measurable PLA2 activity, whereas the other half had no
detectable activity under our assay conditions.
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FIG. 2. The relationship between the total PLA2 activity and the volume
of GCF sampled for 30s (A) and or probing depth (B). There is no
significant relationship between the enzyme activity and either the volume
or the probing depth. (Pearson product moment correlation coefficients.)
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Table 1. PLA2 activity in GCF in the presence or absence of
bleeding on probing
Bleeding Number PLA2 activity (pmol/h/sample)
on probing of sites (mean -t- S.E.)
Presence 67 42.0 -t- 8.4
Absence 41 16.2 ___
4.8
PLA2 activity in GCF is compared between two groups, one
showed BOP and the other did not. (p < 0.02; Mann-Whitney
U test)
with a mean_-FS.E. (n=108) of 5.6_+0.2mm,
respectively. No relationship was found between
the enzyme activity and either the volume or the
probing depth.
Although clinical parameters such as probing
depth and the GCF volume have some limitations,
bleeding upon probing (BOP) is a fairly accurate
clinical sign of active disease.21 Thus the sites were
assigned to two groups by using the marker, BOP.
Table 1 shows that 67 and 41 sites were in the BOP
positive and negative groups respectively. The
enzyme level in the BOP positive group was about
2.5-fold higher than that in the negative group.
It is possible that the high levels of the enzyme
activity detected in GCF partially resulted from
blood and/or saliva that might have entered the
GCF at the sampling sites. PLAz levels in both
saliva and sampled blood were determined as shown
in Fig. 3. The mean -+- S.E. ofPLA2 activity in GCF
was 110.6 41.2 pmol/h/l (n 18), whereas that
in blood was 3.6 _-+ 3.6 pmol/h/#l. No PLA2 activity
was detected in saliva. These results suggested that
the enzyme activity detected in GCF was only from
gingival tissue around the crevice. To confirm this
further, the PLA2 activity in gingival tissue taken
on periodontal therapy (curettage) from the seven
patients was measured and compared with that in
150
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FIG. 3. PLA2 activity in GCF, blood and saliva. The activity was almost
negligible in the blood when compared with that of GCF and no activity
was present in saliva from the same patients. (*p < 0.03, compared with
blood or saliva: Wilcoxon signed-rank test.)
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FIG. 4. Linear correlation between PLA2 activity in the gingiva and GCF.
(p < 0.001 Pearson product moment correlation coefficients.)
GCF of the same sites. As shown in Fig. 4, there
was a highly significant correlation (r-0.93)
between PLA2 activity in GCF and in the gingival
tissue. These data indicated that the PLA2 activity
detected in GCF was mainly from the periodontal
tissue around the sites.
The PLA2 activity in GCF was determined before
and after the periodontal treatment at 19 sites. The
levels of PLA2 activity were significantly decreased
after treatment, suggesting a relationship between
the enzyme activity and periodontal disease (Fig. 5).
We therefore examined more precisely whether the
PLAz activity in GCF reflects periodontal condi-
tions (active phase or inactive phase). Thus, among
the 19 sites, 14 where BOP was positive were
selected and the activity was measured before and
150
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FIG. 5. Changes in PLA2 activity in GCF after treatment. PLA2 activity in
GCF decreased significantly after treatment (62.4 ___
13.8 vs. 2.4 -t- 1.2
pmol/h; p < 0.001 Wilcoxon signed-rank test.)
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Table 2. Changes in PLA2 activity in GCF after periodontal
treatment
PEA2 activity (pmol/h/sample)
BOP (mean -I- S.E.)
Number
Before After of sites Before After
-I- -t- {
5
N.S.
55.2 += 1N3.2.S.
5.4 _+j 3.6
+ 9 78.0 + 24.6 0.6 + 0.6 -r T
In 14 sites where BOP were positive before periodontal
treatment, the changes of PLA2 activity in GCF were compared
between two groups, one shows that BOP became negative
after treatment and the other shows BOP remained positive.
(N.S.I: not significant *p < 0.01, Wilcoxon signed-rank test;
N.S.2: not significant, Mann-Whitney U test)
after periodontal treatment (Table 2). The levels of
PLA2 activity in GCF at nine sites where BOP
became negative after treatment, were significantly
decreased to 0.8% of those before treatment.
However, in five sites where BOP remained
positive despite treatment, there were no significant
changes in the enzyme activity.
Discussion
The PLA2 activity in GCF from patients with
periodontal disease was determined. About half the
GCF samples from the sites examined had
detectable PLA2 activity, whereas the other half had
none under the present assay conditions (Fig. 1).
These data suggest that there is no relationship
between the enzyme activity and the disease.
However, all 108 sites were divided into two groups
by means of a marker for the active stage of
periodontal inflammation, BOP, then the activity
between the two groups was compared. The level
of activity in the positive group was about 2.5 times
higher than that in the negative group (Table 1).
Furthermore, when 19 sites were selected from
among those where PLA2 activity was detected, and
the activity in GCF was measured both before and
after periodontal therapy, there was a significant
decrease in the enzyme activity of GCF after
treatment (Fig. 5). Though the total number of sites
examined (five and nine) were not necessarily
enough to allow interpretation of the results from
Table 2, it may be of more interest that when BOP
positive sites became negative after periodontal
therapy, the activity markedly decreased to about
0.8% of that before therapy. In contrast, when the
BOP positive sites remained unchanged even after
treatment, the activity decreased to about 10%, but
it was not statistically different from that before
therapy (Table 2). Since periodontal inflammation
typically has a relatively short active phase where
tissue destruction occurs, then reaches a prolonged
resting stage where apparent changes (destruction)
are not observed,
2s the results in this study indicate
that the activity reflects the periodontal disease
stage and that it can be a marker for the active phase
of this disease.
A trace of activity was found in peripheral blood
that flowed from periodontal tissue into the
gingival crevice (periodontal pocket) upon period-
ontal examination (probing) and no activity in
saliva from the oral cavity was found (Fig. 3). There
was a close relationship between the activity in both
GCF and the periodontal tissue taken from the same
sites (Fig. 4). These results indicated that the
activity detected in GCF was from that produced
in the tissues then secreted into the crevice.
In inflammatory disorders, such as rheumatoid
arthritis,
11 acute pancreatitis
12 and Crohn’s disease,
6
the activity of extracellular PLA2 in the serum is
correlated with disease activity and the measure-
ment of PLA2 activity has been proved to be a
useful means of diagnosis. High levels of IL-1/
26
and/or TNF7 in synovial fluid from patients with
arthritis and in GCF from patients with periodontal
disease have been reported. 14’28 Since our previous
studies demonstrated that these cytokines induce
PLA2 activity in rat gingival fibroblasts, PLA2
activity detected in GCF may result from similar
events in periodontal tissue.
To the best of our knowledge, this study is the
first to demonstrate the presence of PEA2 activity
in GCF from patients with periodontal disease. The
results suggest that measuring PLA2 activity in
GCF will be a quantifiable marker of periodontal
disease activity.
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